NL9320021A - Farmaceutische samenstellingen die nifedipine bevatten en een werkwijze voor de bereiding daarvan. - Google Patents

Farmaceutische samenstellingen die nifedipine bevatten en een werkwijze voor de bereiding daarvan. Download PDF

Info

Publication number
NL9320021A
NL9320021A NL9320021A NL9320021A NL9320021A NL 9320021 A NL9320021 A NL 9320021A NL 9320021 A NL9320021 A NL 9320021A NL 9320021 A NL9320021 A NL 9320021A NL 9320021 A NL9320021 A NL 9320021A
Authority
NL
Netherlands
Prior art keywords
nifedipine
polyvinylpyrrolidone
composition
acrylic
copolymer
Prior art date
Application number
NL9320021A
Other languages
English (en)
Dutch (nl)
Original Assignee
Ethical Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethical Pharma Ltd filed Critical Ethical Pharma Ltd
Publication of NL9320021A publication Critical patent/NL9320021A/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
NL9320021A 1992-01-13 1993-01-12 Farmaceutische samenstellingen die nifedipine bevatten en een werkwijze voor de bereiding daarvan. NL9320021A (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9200607 1992-01-13
GB929200607A GB9200607D0 (en) 1992-01-13 1992-01-13 Pharmaceutical compositions containing nifedipine and process for the preparation thereof

Publications (1)

Publication Number Publication Date
NL9320021A true NL9320021A (nl) 1995-06-01

Family

ID=10708487

Family Applications (1)

Application Number Title Priority Date Filing Date
NL9320021A NL9320021A (nl) 1992-01-13 1993-01-12 Farmaceutische samenstellingen die nifedipine bevatten en een werkwijze voor de bereiding daarvan.

Country Status (24)

Country Link
US (1) US5594013A (da)
EP (1) EP0620733B1 (da)
JP (1) JPH07503003A (da)
AT (1) ATE191144T1 (da)
AU (1) AU659529B2 (da)
CA (1) CA2126864A1 (da)
DE (2) DE69328245T2 (da)
DK (2) DK0620733T3 (da)
ES (1) ES2146227T3 (da)
FI (1) FI943316A0 (da)
GB (2) GB9200607D0 (da)
HU (2) HU219338B (da)
IS (1) IS1620B (da)
MY (1) MY110660A (da)
NL (1) NL9320021A (da)
NO (1) NO305223B1 (da)
NZ (1) NZ246374A (da)
PH (1) PH30985A (da)
PL (1) PL170935B1 (da)
PT (1) PT620733E (da)
RU (1) RU2106139C1 (da)
SE (1) SE9402457L (da)
WO (1) WO1993013773A1 (da)
ZA (1) ZA93195B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005262A1 (en) * 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5871776A (en) * 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
CA2231050A1 (en) * 1995-09-07 1997-03-13 Biovail International Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
CO4771151A1 (es) * 1996-01-19 1999-04-30 Rachitzky Falicman Pablo Alberto Procedimiento para la elaboracion de una preparacion farmace utica que contiene nifedipina y la preparacion farmaceutica obtenida mediante el mismo
IL123505A (en) 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
IT1284604B1 (it) * 1996-09-27 1998-05-21 Roberto Valducci Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6264872B1 (en) 1997-12-30 2001-07-24 Kimberly-Clark Worldwide, Inc. Method of forming thin, embossed, textured barrier films
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6168806B1 (en) 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
ATE419834T1 (de) * 2000-11-20 2009-01-15 Elan Pharma Int Ltd Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US20040253312A1 (en) * 2001-09-28 2004-12-16 Sowden Harry S. Immediate release dosage form comprising shell having openings therein
EP1355633B1 (en) * 2001-12-19 2005-01-19 AstraZeneca AB NEW FILM COATING containing an ethyl acrylate/methyl methacrylate copolymer and polyvinyl acetate
US6620900B2 (en) * 2002-02-07 2003-09-16 Isp Investments Inc. Proliferous copolymer of vinyl pyrrolidone and vinyl acetate
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
RU2220725C1 (ru) * 2002-08-01 2004-01-10 Закрытое акционерное общество "Брынцалов-А" Антиангинальное, антигипертензивное средство
EP1539270A1 (en) * 2002-09-18 2005-06-15 Medtronic Vascular, Inc. Controllable drug releasing gradient coatings for medical devices
AU2006232896A1 (en) 2005-04-06 2006-10-12 Mallinckrodt Inc. Matrix-based pulse release pharmaceutical formulation
WO2007106111A2 (en) * 2005-07-01 2007-09-20 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising nilvadipine
EP2214651A1 (en) * 2007-10-25 2010-08-11 Bayer Yakuhin, Ltd. Nifedipine-containing press coated tablet and method of preparing the same
RU2629843C1 (ru) * 2016-05-24 2017-09-04 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Способ получения мази нифедипина (варианты)
CN115844845B (zh) * 2022-08-29 2025-03-14 迪沙药业集团有限公司 一种硝苯地平缓释制剂及制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
EP0047894B2 (en) * 1980-09-05 1990-09-05 Argus Chemical Corporation Homogeneous storage-stable liquid barium-cadmium-triphosphite stabilizer systems for polyvinyl chloride resins
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
DE3270785D1 (en) * 1981-10-29 1986-05-28 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
DE3580384D1 (de) * 1984-04-09 1990-12-13 Toyo Boseki Praeparat mit verzoegerter freigabe zum aufbringen auf die schleimhaeute der mundhoehle.
DE3424553A1 (de) * 1984-07-04 1986-01-09 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
FR2579510B1 (fr) * 1985-03-29 1989-12-15 Demler Sa Ets Table vibrante pour la fabrication de produits en beton
FR2585174B1 (fr) * 1985-07-16 1987-11-27 Eurofarad Procede de fabrication d'un composant capacitif multicouche a dielectrique ceramique du type cordierite, et composant ainsi obtenu
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4970075A (en) * 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
IE59540B1 (en) * 1987-01-09 1994-03-09 Elan Corp Sustained release capsule or tablet formulation
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
GB8722306D0 (en) * 1987-09-22 1987-10-28 Aps Research Ltd Sustained-release formulation
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
ES2077023T3 (es) * 1989-03-10 1995-11-16 Yamanouchi Pharma Co Ltd Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
JPH0729926B2 (ja) * 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物

Also Published As

Publication number Publication date
HUT67426A (en) 1995-04-28
FI943316A7 (fi) 1994-07-12
DE69328245T2 (de) 2000-10-12
GB2277872A (en) 1994-11-16
DK0620733T3 (da) 2000-07-24
NO305223B1 (no) 1999-04-26
US5594013A (en) 1997-01-14
HU219338B (en) 2001-03-28
SE9402457L (sv) 1994-09-12
PL170935B1 (pl) 1997-02-28
ATE191144T1 (de) 2000-04-15
IS1620B (is) 1996-10-18
ZA93195B (en) 1993-08-16
PL300638A1 (en) 1994-03-21
DE4390075T1 (de) 1994-12-01
PT620733E (pt) 2000-08-31
AU3263693A (en) 1993-08-03
HU210539A9 (en) 1995-05-29
AU659529B2 (en) 1995-05-18
PH30985A (en) 1997-12-23
SE9402457D0 (sv) 1994-07-12
EP0620733B1 (en) 2000-03-29
GB9413101D0 (en) 1994-08-31
IS3966A (is) 1993-07-14
WO1993013773A1 (en) 1993-07-22
EP0620733A1 (en) 1994-10-26
JPH07503003A (ja) 1995-03-30
FI943316L (fi) 1994-07-12
RU94035739A (ru) 1996-09-20
NZ246374A (en) 1995-07-26
NO942622D0 (no) 1994-07-12
MY110660A (en) 1999-01-30
NO942622L (no) 1994-07-12
HU9401850D0 (en) 1994-09-28
RU2106139C1 (ru) 1998-03-10
GB9200607D0 (en) 1992-03-11
GB2277872B (en) 1995-10-04
CA2126864A1 (en) 1993-07-22
ES2146227T3 (es) 2000-08-01
FI943316A0 (fi) 1994-07-12
DK83794A (da) 1994-07-11
DE69328245D1 (de) 2000-05-04

Similar Documents

Publication Publication Date Title
NL9320021A (nl) Farmaceutische samenstellingen die nifedipine bevatten en een werkwijze voor de bereiding daarvan.
RU2136283C1 (ru) Препарат с контролируемым высвобождением лекарства и способ его получения, способ лечения
EP0284407B1 (en) 3'-azido-3'-deoxythymidine controlled-release formulations
NL1022151C2 (nl) Farmaceutische pellets die tamsulosine omvatten en een proces voor het maken ervan.
JP2753297B2 (ja) 薬学的製剤
JP2930875B2 (ja) γ−ヒドロキシ酪酸塩による制御放出能をもつ薬化学組成物
CA2304110C (en) Theophylline sustained release tablet
RS50054B (sr) Kompozicije oksikodona sa kontrolisanim oslobađanjem
JP2003513882A (ja) ジバルプロエックスナトリウムの制御放出製剤
JPS5829717A (ja) 医薬用賦形剤
Harsha et al. Ofloxacin targeting to lungs by way of microspheres
Karvekar et al. A brief review on sustained release matrix type drug delivery system
US20020076444A1 (en) Novel method for obtaining microspheres and resulting products
EP1572160A2 (en) Process for manufacturing sustained release microbeads containing venlafaxine hci
US5492700A (en) Process and composition for the development of controlled release gemfibrozil dosage form
Samirkumar et al. Formulation development and evaluation of microspheres containing duloxetine hydrochloride
EP1680098A1 (en) Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
KR20030076634A (ko) 의약 조성물
JP2687448B2 (ja) イブプロフェン徐放性製剤
US5358723A (en) Process and composition for the development of controlled release gemfibrozil dosage form
Sinha et al. Influence of operational variables in multi-particulate delayed release systems for colon-targeted drug delivery of celecoxib using extrusion spheronization
JP2947841B2 (ja) 徐放性固形製剤
Kumar Design, Development and Characterization of Verapamil Hydrochloride Pulsincap: In Vitro and In Vivo
JPS6024765B2 (ja) セフアレキシンの持続性製剤の製造方法
EP0614358A1 (en) Process and composition for the development of controlled release gemfibrozil dosage form

Legal Events

Date Code Title Description
BI The patent application has been withdrawn
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
BV The patent application has lapsed